St. Jude

A proportion of pediatric ALL patients appear to have germline TP53 mutations associated with later diagnoses, poorer outcomes, and increased secondary cancer risk.

Right Patient Right Drug will use the PharmacoScan platform to perform preventive pharmacogenetic testing under St. Jude's PG4KDS program.  

Genome and transcriptome sequences from hundreds of pediatric cancer cases led to somatic mutations and fusions suspected of producing potentially targetable antigens.

This Week in Nature

In Nature this week: new Neanderthal mitochondrial genome, and more.

Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.

This Week in Cell

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

Suspicious variants were uncovered through analyses of pediatric cancer survivors from the St. Jude Lifetime Cohort Study and Childhood Cancer Survivor Study.

Results from up to eight stages of mouse or human retina development highlight the importance of histone modifications and other epigenetic shifts during differentiation.

Roughly one-fifth of adult cases of acute lymphoblastic leukemia are marked by Philadelphia chromosome-like expression. 

Children's Genomics

US News and World Report takes a look at genomics' role at pediatric hospitals.

Pages

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.